MediciNova Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast)
Excerpt from the Press Release:
LA JOLLA, Calif., July 21, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the initiation of a first-in-human clinical study to evaluate the pharmacokinetics and bioavailability of a new MN-166 (ibudilast) parenteral formulation. The newly developed MN-166 (ibudilast) formulation will provide an additional option for health care providers to administer MN-166 (ibudilast), in addition to the current oral formulation.
Kazuko Matsuda, MD, PhD, MPH, Chief Medical Officer of MediciNova, Inc., commented, “We have been working on developing an injectable formulation of MN-166 and are excited about this milestone in our pharmaceutical development program. This new formulation allows the administration of MN-166 not only in acute settings to achieve a desired rapid effect of MN-166, but for indications requiring injections in precise locations such as intra-ocular, intra-articular and intrathecal routes. With MN-166 expected to be effective to treat a variety of diseases, we believe expanding to a parenteral formulation increases the feasibility of treating more target indications, thus increasing the value of MN-166.”
About MN-166 (ibudilast)
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), progressive MS (multiple sclerosis), and DCM (degenerative cervical myelopathy); and is also in development for glioblastoma, CIPN (chemotherapy-induced peripheral neuropathy), and substance use disorder. In addition, MN-166 (ibudilast) was evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS).
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?